[Summer Rewind] The Concept of “In-Silico Medicine”

Did you miss these insights published this year? Now is the time to catch up. This summer, we offer you the opportunity to discover or rediscover the medical news published in our affiliated publication, DirectIndustry e-magazine. In this article, we explore the concept of clinical and pharmaceutical trials through digital simulation. This is also called “In-Silico Medicine.”

Advances in medical imaging, computational power, and numerical algorithms enable accurate modeling of the entire human body. This capability has the potential to transform medical research and product development.

Specifically, the concept of “in-silico medicine” involves simulating the interaction of medical products with the body without real-body testing. The American Food and Drug Administration (FDA) has already authorized the market release of medical devices tested through digital simulation.

This approach addresses concerns related to development time, time to market, market entry costs, and the ability to test more candidates. Notably, in-silico testing is particularly advantageous for rare diseases, where establishing patient cohorts for traditional validation can be challenging.

Explore the full article for more details: In Vivo, In Vitro, In Silico: Clinical and Pharmaceutical Trials Through Digital Simulation